Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Phathom Pharmaceuticals, Inc. PHAT
$13.72
+$0.55 (4.02%)
На 18:01, 12 мая 2023
+118.66%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
525852180.00000000
-
week52high
13.44
-
week52low
5.84
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.34485800
-
EPS
-5.20000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:00
Описание компании
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 03 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 03 авг 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 06 мая 2022 г. |
| Goldman Sachs | Neutral | Sell | 12 мая 2021 г. |
| Jefferies | Buy | 21 окт 2022 г. | |
| BMO Capital | Outperform | Outperform | 14 ноя 2022 г. |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| Needham | Buy | Buy | 04 янв 2023 г. |
| BMO Capital | Outperform | Outperform | 04 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Curran Terrie | D | 176807 | 5821 | 20 янв 2023 г. |
| Curran Terrie | D | 162500 | 162500 | 19 янв 2023 г. |
| Curran Terrie | A | 182628 | 97500 | 19 янв 2023 г. |
| Nabulsi Azmi | A | 75000 | 75000 | 19 янв 2023 г. |
| Nabulsi Azmi | A | 89567 | 45000 | 19 янв 2023 г. |
| Henderson Molly | A | 55000 | 55000 | 19 янв 2023 г. |
| Henderson Molly | A | 78047 | 33000 | 19 янв 2023 г. |
| Parikh Asit | A | 17500 | 5000 | 12 янв 2023 г. |
| Henderson Molly | D | 43341 | 2159 | 21 ноя 2022 г. |
| Curran Terrie | D | 83720 | 1526 | 21 ноя 2022 г. |
Новостная лента
Why Shares of Phathom Pharmaceutical Jumped This Week
The Motley Fool
28 янв 2023 г. в 13:58
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
Zacks Investment Research
05 янв 2023 г. в 12:02
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
Phathom Pharma: Approved Drugs, Upcoming PDUFA, Smallish Addressable Market
Seeking Alpha
10 ноя 2022 г. в 12:38
PHAT, a Takeda spinoff, has a drug approved in H. pylori. The same drug has a PDUFA in a GERD subtype.
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
07 сент 2022 г. в 08:15
FLORHAM PARK, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.